Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab beyond progression in advanced non-squamous NSCLC
jRCT1080221719Phase 4
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing Standard of care + bevacizumab beyond progression with Standard of care alone (2 arms).
02
Drugs
bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT1080221719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221719.